PH12021500006A1 - Methods of treatment and prevention of alzheimer's disease - Google Patents

Methods of treatment and prevention of alzheimer's disease

Info

Publication number
PH12021500006A1
PH12021500006A1 PH12021500006A PH12021500006A PH12021500006A1 PH 12021500006 A1 PH12021500006 A1 PH 12021500006A1 PH 12021500006 A PH12021500006 A PH 12021500006A PH 12021500006 A PH12021500006 A PH 12021500006A PH 12021500006 A1 PH12021500006 A1 PH 12021500006A1
Authority
PH
Philippines
Prior art keywords
methods
disease
alzheimer
subject
prevention
Prior art date
Application number
PH12021500006A
Other languages
English (en)
Inventor
Johan Luthman
Chad J Swanson
Yong Zhang
Shobha Dhadda
Jinping Wang
Lynn Kramer
Original Assignee
Eisai R And D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R And D Man Co Ltd filed Critical Eisai R And D Man Co Ltd
Publication of PH12021500006A1 publication Critical patent/PH12021500006A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PH12021500006A 2018-07-24 2021-01-21 Methods of treatment and prevention of alzheimer's disease PH12021500006A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US201962874684P 2019-07-16 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Publications (1)

Publication Number Publication Date
PH12021500006A1 true PH12021500006A1 (en) 2021-09-13

Family

ID=67551415

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021500006A PH12021500006A1 (en) 2018-07-24 2021-01-21 Methods of treatment and prevention of alzheimer's disease

Country Status (11)

Country Link
US (1) US20210324056A1 (cg-RX-API-DMAC7.html)
EP (1) EP3826674A2 (cg-RX-API-DMAC7.html)
JP (3) JP7541505B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210039402A (cg-RX-API-DMAC7.html)
CN (2) CN118924896A (cg-RX-API-DMAC7.html)
AU (2) AU2019309938B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107370A1 (cg-RX-API-DMAC7.html)
IL (3) IL310132B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000778A (cg-RX-API-DMAC7.html)
PH (1) PH12021500006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023530A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
PT4121007T (pt) * 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023114586A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3405489A1 (en) * 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Also Published As

Publication number Publication date
MX2021000778A (es) 2021-03-31
US20210324056A1 (en) 2021-10-21
CA3107370A1 (en) 2020-01-30
IL310132B1 (en) 2025-11-01
AU2019309938A1 (en) 2021-03-11
BR112021001272A2 (pt) 2021-04-27
IL323583A (en) 2025-11-01
AU2019309938B2 (en) 2026-04-02
CN112805031A (zh) 2021-05-14
WO2020023530A2 (en) 2020-01-30
WO2020023530A3 (en) 2020-03-12
JP2024112859A (ja) 2024-08-21
JP2021532126A (ja) 2021-11-25
KR20210039402A (ko) 2021-04-09
IL310132B2 (en) 2026-03-01
IL280315B1 (en) 2024-02-01
TW202019471A (zh) 2020-06-01
IL280315B2 (en) 2024-06-01
EP3826674A2 (en) 2021-06-02
CN118924896A (zh) 2024-11-12
IL280315A (en) 2021-03-25
IL310132A (en) 2024-03-01
JP2026097906A (ja) 2026-06-16
JP7541505B2 (ja) 2024-08-28
JP7875901B2 (ja) 2026-06-18
AU2026204903A1 (en) 2026-07-09

Similar Documents

Publication Publication Date Title
WO2020023530A3 (en) Methods of treatment and prevention of alzheimer's disease
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
FI3927337T3 (fi) 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikea-asteisen masennuksen hoitoon
MX2012002082A (es) Terapia de acetato de glatiramero de baja frecuencia.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
EP4272828A3 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX361741B (es) Tratamientos médicos a base de anamorelina.
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
MX2024002567A (es) Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
EA202193178A1 (ru) Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MX2021013807A (es) Tratamiento de enfermedad ocular.
IL285160A (en) Low dose pridopidine for parkinson’s disease and other diseases associated with parkinsonism
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
WO2022043273A3 (en) Oral care composition comprising a fructanase
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.